Clemidsogene lanparvovec

Gene therapy / editing

Also known as RGX-121

On holdsponsor decision

Evidence outlook · program status

On hold (2026-08), on a safety finding

FDA placed RGX-121 on clinical hold after asymptomatic spine MRI findings in five CAMPSIITE participants; REGENXBIO does not expect to resubmit the BLA in the near term (release of 2026-08-24). The trials below are the program's evidence history; no evidence signal is assigned while development is paused.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Mucopolysaccharidosis Type II
Phase 2/3 (1)
Mucopolysaccharidosis Type II
NCT03566043 · REGENXBIO Inc.
2018-09-27 – 2025-08 · Mucopolysaccharidosis Type II (MPS II)
What this study did
Phase 1/2 (1)
Mucopolysaccharidosis Type II
NCT04571970 · REGENXBIO Inc.
2021-03-11 – 2024-05-23 · Mucopolysaccharidosis Type II (MPS II)
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Mucopolysaccharidosis Type II: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Clemidsogene Lanparvovec: this drugPhase 3Gene therapy / editingIduronate-2-sulfatase (IDS)not yet gradedNo reviewed efficacy summary in this indication
Tividenofusp Alfa (Avlayah)ApprovedProtein / enzyme therapeuticIduronate-2-sulfatase (IDS)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Development is on hold since 2026-08 (source ↗). ClinicalTrials.gov still lists the estimated primary-completion dates below; they may not read out as listed.

2028 (1)
April 2028 (1)
Phase 3Mucopolysaccharidosis Type IIActive not recruitingProgramme on hold
Est. primary completion 2028-04-30 · NCT07236606 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 February 2026FDA action dateFDA extends PDUFA date for RGX-121 BLA to February 8, 2026
US, FDA · Source ↗
7 February 2026Complete response letterFDA issues Complete Response Letter for the RGX-121 BLA in MPS II
US, FDA · REGENXBIO Inc. · Source ↗
9 November 2025FDA action datePDUFA target action date set for RGX-121
US, FDA · Source ↗
13 May 2025Filing acceptedFDA accepts BLA for RGX-121 in MPS II
US, FDA · Source ↗
13 May 2025Priority reviewFDA grants Priority Review to RGX-121 BLA
US, FDA · Source ↗